Table 1. Patient Characteristicsa.
| Characteristic | No. (%) | ||
|---|---|---|---|
| All (n = 30) | No ICANS (n = 19) | Any ICANS (n = 11) | |
| Age, median (range), y | 64 (22-80) | 64 (22-80) | 64 (33-79) |
| Sex | |||
| Female | 12 (40) | 7 (37) | 5 (45) |
| Male | 18 (60) | 12 (63) | 6 (55) |
| Race | |||
| Asian | 1 (3) | 1 (5) | 0 |
| Black | 2 (7) | 1 (5) | 1 (18) |
| Hispanic | 1 (3) | 1 (5) | 0 |
| White | 26 (87) | 16 (84) | 10 (91) |
| Cancer history | |||
| DLBCL | 23 (77) | 15 (79) | 8 (73) |
| Stage at initial diagnosis, median | 3 | 3 | 3 |
| Tumor burden,b mean (SD), mm3 | 133.1 (233) | 140.2 (288) | 122.1 (117) |
| CNS involvement | 7 (23) | 5 (26) | 2 (18) |
| History of | |||
| Vincristine exposure | 28 (93) | 18 (95) | 10 (91) |
| Cytarabine exposure | 6 (20) | 3 (16) | 3 (2) |
| High-dose methotrexate | 5 (17) | 3 (16) | 2 (18) |
| Intrathecal methotrexate | 5 (17) | 3 (16) | 2 (18) |
| CNS radiotherapy | 3 (10) | 3 (16) | 0 |
| Neurologic history | |||
| Neurologic disease, not related to cancer | 5 (17) | 2 (10) | 3 (27) |
| Neuropathy | 17 (57) | 10 (52.6) | 7 (63.6) |
| CAR T-cell product | |||
| Axicabtagene ciloleucel | 19 (63) | 12 (63) | 7 (64) |
| Tisagenlecleucel | 4 (13) | 3 (16) | 1 (9) |
| Brexucabtagene autoleucel | 1 (3) | 0 | 1 (9) |
| Experimental CD19 CAR (2nd generation) | 6 (20) | 4 (21) | 2 (18) |
Abbreviations: CAR, chimeric antigen receptor; CD19, cluster of differentiation 19; CNS, central nervous system; DLBCL, diffuse large B-cell lymphoma; ICANS, immune effector cell–associated neurotoxicity syndrome.
a
Demographic and oncologic characteristics of the study cohort. Expanded version with ICANS subgroups is in the eTable in the Supplement.
b
Mean tumor volume was derived from total lesion burden on preinfusion positron emission tomography scans (see eMethods in the Supplement).